A company looking to buyout another company or to partner with a company looks at it's asset and intellectual property that can either benefit them.
In a buyout they can flush the employees so it's not a big consideration.
In a partnership it would be a consideration and would affect negotiations as to control of the partnered indication.
You are correct on the anti NP rhetoric , they want him gone in order to get Cytodyn for less. He is getting recognition for LL on an international scale and will keep getting the value increased. The prospects of a buyout or partnerships will keep increasing.
Please clarify how CEO would not be an issue in a “partnership “.: If CYDY partners with somebody NP will be calling the shots from the CYDY perspective. I don’t see that as an appealing option to a BP partner.
Market Data 
Markets 
AI
